{"preliminary_commentary":{"by_channel":{"youtube":7,"x_thread":7,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05663866\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":"post-osimertinib EGFRm NSCLC","name":"SKIPPirr","nct_id":"NCT05663866","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=skippirr-nct05663866. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participant will receive following treatments in 4 different cohorts prior to administration of combination therapy of IV Amivantamab and oral Lazertinib (anti-cancer regimen): dexamethasone dose-1 in Cohort A; dexamethasone dose-2 in Cohort A2; montelukast in Cohort B; and methotrexate in Cohort C.","label":"Background Anti-cancer Therapy with Amivantamab Plus Lazertinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":68,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Montelukast","otherNames":[],"type":"DRUG"},{"name":"Methotrexate","otherNames":[],"type":"DRUG"},{"name":"Amivantamab","otherNames":["JNJ-61186372"],"type":"DRUG"},{"name":"Lazertinib","otherNames":["JNJ-73841937"],"type":"DRUG"}],"last_update":"2026-11-03","lead_sponsor":"Janssen Research & Development, LLC","official_title":"Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-03-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1","timeFrame":"Cycle 1 Day 1 (each cycle of 28 days)"}],"references":[{"citation":"Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, Zugazagoitia J, Kim YJ, Chiu CH, Kim SW, Nadal E, Gil-Bazo I, Murphy SP, Anderson BG, Xia Y, Wang G, Bauml JM, Chioda M, Simoes J, Mahadevia PJ, Lopes G. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report. J Thorac Oncol. 2025 Jun;20(6):809-816. doi: 10.1016/j.jtho.2025.01.018. Epub 2025 Jan 24.","pmid":"39864547","type":"DERIVED"}],"start_date":{"date":"2023-05-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","url":"https://clinicaltrials.gov/study/NCT05663866"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/skippirr-nct05663866"}